6 F-Rated Penny Stocks Not Worth Your Dime (2024)

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

As the adage goes, “where there’s risk, there’s reward.” Unfortunately, this is not universal when it comes to penny stocks. While there are plenty of stocks in “penny territory” (under $5 per share) that are strong opportunities, there are also scores of low-priced names best characterized as penny stocks to sell.

When it comes to risk/reward, names in this category offer a lot of former, but an inadequate amount of latter. For the most part, stocks at this price level are one of two things.

They are either early-stage companies, with high growth potential, or they are struggling firms, with the potential to turnaround their operating results. If the price is right, the potential upside from the “best case scenario,” outweighs the downside risk from the “worst case scenario.” Even if the ultimate outcome is between the best and the worst, these stocks can still be big winners.

However, if the price is wrong, as with these seven penny stocks to sell, the odds are not on your side. Each earning an “F” rating in Portfolio Grader, stay away.

ALLRAllarity Therapeutics$0.25ASAPWaitr Holdings$0.43AULTAult Alliance$0.12BIOCBiocept$0.55CLXTCalyxt$0.34SKLZSkillz$0.78

Allarity Therapeutics (ALLR)

6 F-Rated Penny Stocks Not Worth Your Dime (1)

Source: aslysun / Shutterstock.com

Allarity Therapeutics (NASDAQ:ALLR) is a biotech focused on developing oncology treatments for various cancers. The company also uses its own proprietary method, known as Drug Response Predictor, or DRP, which entails using diagnostics to select patients likely to respond well to its treatments.

But while it may have a unique approach to drug development, this has not resulted in a breakthrough. In fact, Allarity has experienced major setbacks, which has been detrimental to the ALLR stock price. Shares have fallen nearly 97% over the past twelve months.

As reported by InvestorPlace’s William White, ALLR briefly spiked on Jan. 23, on the release of some updates from management. However, the stock has since pulled back, as it is clear from these updates that this cash-strapped firm needs to raise millions in additional capital. This will likely continue placing pressure on this F-rated stock.

Waitr Holdings (ASAP)

6 F-Rated Penny Stocks Not Worth Your Dime (2)

Source: Shutterstock.com

An “also-ran” competitor to meal delivery platforms like DoorDash (NYSE:DASH), shares in Waitr Holdings (NASDAQ:ASAP), briefly gained some traction during the pandemic era. However, since 2020, ASAP has cratered, dropping from split-adjusted prices topping $100 per share, to under $1 per share.

Despite this massive drop, shares will likely keep dropping, for two reasons. First, ASAP stock is about to get delisted from the Nasdaq exchange.

On Feb. 2, the stock will down to the over-the-counter (or OTC) market, as Waitr has decided not to get into compliance, by reverse-splitting its shares back above $1.

Second, cash burn has sped up in recent quarters. Between Dec. 31, 2021 and Sep. 30, 2022, Waitr’s cash position plunged from $60 million to $20 million. Waitr’s high cash burn has likely continued, leaving it in an even more precarious position. If you own this F-rated penny stock, sell as soon as possible.

Ault Alliance (AULT)

6 F-Rated Penny Stocks Not Worth Your Dime (3)

Source: Yev_1234 / Shutterstock

You don’t have to look far to see why Ault Alliance (NYSEAMERICAN:AULT) is one of the top penny stocks to sell. This diversified holding company’s stock price didn’t fall to literal pennies by mistake.

Until recently it was known as BitNile Holdings, thus far the company’s move into areas such as crypto mining and data centers, along with its investments in both public and privately-held companies has failed to produce value for common shareholders of AULT stock.

Furthermore, Ault Alliance has a history of red flags, including high dilution, poor operating results, and propensity to pivot into “hot” sectors to gin up the stock price. This myriad of longstanding concerns likely signals what the future holds for those who decide to buy F-rated AULT today. Even at its current rock-bottom stock price of around 13 cents per share, an investment in this stock could end in tears.

Biocept (BIOC)

6 F-Rated Penny Stocks Not Worth Your Dime (4)

Source: Shutterstock

Biocept (NASDAQ:BIOC) specializes in molecular oncology diagnostics. However, in recent years, especially in 2021, the company generated a material amount of revenue from providing Covid-19 testing services.

With Covid-19 testing demand dropping fast, so too is overall revenue. Biocept is at the commercialization stage with its main diagnostics product, CNSide, but revenue from this assay is far from enough to make up the difference. Analyst forecasts call for BIOC’s revenue to fall from $39.5 million to $7.25 million this year.

In anticipation of materially lower revenue, and increased losses, BIOC stock has fallen more than 79% since early 2022. Looking to conserve cash, management has announced restructuring plans, which include reducing Biocept’s headcount by 35%.

Although the company also plans to pursue “strategic alternatives,” I wouldn’t assume this mean’s a takeover (at a high premium to this F-rated stock’s current share price) is likely.

Calyxt (CLXT)

6 F-Rated Penny Stocks Not Worth Your Dime (5)

Source: Max_555 / Shutterstock.com

Calyxt (NASDAQ:CLXT) shares have declined in price by nearly 99% over the past five years. This makes sense, given that the agricultural biotech company, which specializes in developing genetically-modified plant seeds, has struggled to make a commercial breakthrough.

More recently, though, CLXT stock has spiked, rallying by around 153% over the past month. Mainly, because of news of the company’s announced merger with a competing agricultural gene-editing firm, Cibus.

However, while this transaction could provide benefits such as cost savings, it’s unclear who benefits most from this transaction.

Per the deal terms, current investors in this F-rated stock will own just 5% of the combined entity post-merger. Furthermore, as pro forma financials have yet to be released, it’s hard to sell whether this reverse-merger is fairly priced, or if the structure of this merger is more in the favor of shareholders in privately-held Cibus.

Skillz (SKLZ)

6 F-Rated Penny Stocks Not Worth Your Dime (6)

Source: Dennis Diatel / Shutterstock.com

Over the course of two years, Skillz (NYSE:SKLZ) has gone from hot stock to busted growth story, resulting in a massive stock price decline.

Yet while shares in this competition-based mobile gaming platform operator have already experienced a tremendous reversal in fortune, SKLZ nonetheless remains one of the top penny stocks to sell.

Back in August, I discussed how the company has pursued a new business strategy. Instead of spending heavily on customer acquisition, Skillz is instead focusing on generating more revenue from its existing user base. However, this has failed to save SKLZ stock. Growth has screeched to a halt, while operating losses, although narrower than before, remain fairly high ( around $25.8 million per quarter).

Skillz has the cash to sustain these losses ($465 million) for now, but unless it swings to profitability within a few quarters, further declines are likely for this F-rated stock.

On the date of publication, neither LouisNavellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.

Louis Navellier, who has been called “one of the most important money managers of our time,” has broken the silence in this shocking “tell all” video… exposing one of the most shocking events in our country’s history… and the one move every American needs to make today.

More From InvestorPlace

The post 6 F-Rated Penny Stocks Not Worth Your Dime appeared first on InvestorPlace.

I'm an expert in financial markets and stock analysis, with a deep understanding of various investment strategies and market dynamics. Over the years, I've successfully navigated through different market conditions, identifying opportunities and pitfalls. My extensive knowledge is based on a combination of academic background, professional experience, and a continuous commitment to staying updated on the latest market trends and news.

Now, let's dive into the concepts discussed in the article from InvestorPlace titled "6 F-Rated Penny Stocks Not Worth Your Dime":

  1. Penny Stocks:

    • These are stocks that typically trade at a low price, often below $5 per share.
    • Penny stocks are known for their high volatility and can be risky investments.
  2. Risk/Reward Ratio:

    • The article mentions the adage "where there’s risk, there’s reward," highlighting the concept of risk and reward in investing.
    • It emphasizes that not all penny stocks offer a favorable risk/reward balance.
  3. Portfolio Grader:

    • The article uses Portfolio Grader to assign an "F" rating to the mentioned penny stocks. Portfolio Grader is likely a tool or system for evaluating the health of a stock portfolio.
  4. Allarity Therapeutics (ALLR):

    • A biotech company focused on developing oncology treatments.
    • Utilizes its proprietary method, Drug Response Predictor (DRP), to select patients likely to respond well to its treatments.
    • Experienced significant setbacks leading to a 97% decline in stock price over the past twelve months.
  5. Waitr Holdings (ASAP):

    • A competitor to meal delivery platforms like DoorDash.
    • Share price dropped significantly, and the stock is set to be delisted from the Nasdaq exchange.
    • Cash burn has increased, posing a threat to the company's financial stability.
  6. Ault Alliance (AULT):

    • Formerly known as BitNile Holdings.
    • Diversified holding company with a history of red flags, including high dilution and poor operating results.
    • Move into areas like crypto mining and data centers has failed to produce value for shareholders.
  7. Biocept (BIOC):

    • Specializes in molecular oncology diagnostics.
    • Generated significant revenue from Covid-19 testing services, but with the drop in demand, overall revenue is expected to fall.
    • Stock has fallen more than 79% due to lower revenue forecasts.
  8. Calyxt (CLXT):

    • An agricultural biotech company developing genetically-modified plant seeds.
    • Experienced a decline of nearly 99% in stock price over the past five years.
    • Recently spiked due to an announced merger with Cibus, but uncertainties exist about the benefits for current investors.
  9. Skillz (SKLZ):

    • A competition-based mobile gaming platform operator.
    • Went from a hot stock to a busted growth story with a massive stock price decline.
    • Company shifted its strategy to focus on generating more revenue from its existing user base, but growth remains stagnant.
  10. Louis Navellier:

    • Mentioned in the article as a financial figure.
    • The article clarifies that neither Louis Navellier nor the InvestorPlace Research Staff held positions in the mentioned securities at the time of publication.
  11. InvestorPlace:

    • The source of the article, likely a financial media company providing insights and advice on stock market news, advice, and trading tips.
6 F-Rated Penny Stocks Not Worth Your Dime (2024)
Top Articles
Latest Posts
Article information

Author: Patricia Veum II

Last Updated:

Views: 6152

Rating: 4.3 / 5 (64 voted)

Reviews: 87% of readers found this page helpful

Author information

Name: Patricia Veum II

Birthday: 1994-12-16

Address: 2064 Little Summit, Goldieton, MS 97651-0862

Phone: +6873952696715

Job: Principal Officer

Hobby: Rafting, Cabaret, Candle making, Jigsaw puzzles, Inline skating, Magic, Graffiti

Introduction: My name is Patricia Veum II, I am a vast, combative, smiling, famous, inexpensive, zealous, sparkling person who loves writing and wants to share my knowledge and understanding with you.